AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2025

Jul 30, 2025

32312_dirs_2025-07-30_e9549fd7-ce47-45f5-b9d7-c89fce17ccee.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-07-28

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-28	Ordinary Shares	M	16500	—	Acquired	49014	Direct
2025-07-28	Ordinary Shares	S	7522	$19.14	Disposed	41492	Direct

Footnotes

F1: Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event.

F2: Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.

F3: Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units.